Should I Buy PRTA? PRTA 2026 Analysis

Should You Buy Prothena Corporation PLC (PRTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

9.400

1 Day change

8.42%

52 Week Range

16.050

Analysis Updated At

2026/02/27

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Prothena Corporation PLC (PRTA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks positive catalysts, has weak financial performance, and shows no significant trading trends or signals. Holding off on investment until better indicators emerge would be prudent.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 26.598, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the pre-market price is down 1.27%, and the stock is trading near its support level (S1: 8.378). The technicals do not indicate a strong buy signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity.

Neutral/Negative Catalysts

Financial performance is weak with significant YoY declines in revenue (-99.01%), net income (-62.75%), and EPS (-62.96%). Pre-market price is down 1.27%, and there are no recent trading trends or congress activity.

Financial Performance

In Q4 2025, revenue dropped significantly to 21,000 (-99.01% YoY), net income fell to -21,589,000 (-62.75% YoY), and EPS decreased to -0.4 (-62.96% YoY). Gross margin remained stable at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

5 Analyst Rating

Wall Street analysts forecast PRTA stock price to rise

4 Buy

0 Hold

1 Sell

Moderate Buy

Current: 8.670

Low

Averages

22.2

High

Current: 8.670

Low

Averages

22.2

High

BofA

Tazeen Ahmad

Underperform

maintain

$4 -> $8

AI Analysis

2025-11-24

Reason

BofA

Tazeen Ahmad

Price Target

$4 -> $8

AI Analysis

2025-11-24

maintain

Underperform

Reason

BofA analyst Tazeen Ahmad raised the firm's price target on Prothena (PRTA) to $8 from $4 and keeps an Underperform rating on the shares. Prothena no longer plans to disclose further data for its Alzheimer's drug PRX012, notes the firm, which removed value for the program from its model and is shifting focus on valuation to two Phase 3 assets under development by partners Novo (NVO) and Roche (RHHBY) - Coramitug for ATTR-cardiomyopathy and prasinezumab for early-stage Parkinson's disease. While both programs will have begun Phase 3 studies by year-end, which the firm views favorably for Prothena, the firm adds that each drug will need several years to reach the market and their competitive positioning in the case of Coramitug and clinical efficacy in the case of prasinezumab are "uncertain."

H.C. Wainwright

Buy

maintain

$20 -> $30

2025-11-07

Reason

H.C. Wainwright

Price Target

$20 -> $30

2025-11-07

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Prothena to $30 from $20 and keeps a Buy rating on the shares. The firm believes the market is overlooking the company's two partnered Phase 3 programs and a partnered Phase 2 asset with blockbuster potential.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRTA

Unlock Now

PRTA Should I Buy

PRTA Should I Buy

Should You Buy Prothena Corporation PLC (PRTA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch